Longevity Health Holdings Sees 58.5% Stock Surge
By ATTN Desk · Editorial oversight: Sean Han
Longevity Health Holdings Inc (XAGE)
Introduction
Longevity Health Holdings Inc, formerly Carmell Corporation, trades on the NASDAQ Capital Market under the ticker XAGE. On March 10, 2025, the company adopted its current name and corporate logo to reflect a broader focus on longevity and healthy aging.
| Metric | Value |
|---|---|
| Price (May 22, 2025) | $4.85 |
| Change (1-day) | +58.50% |
| Volume | 3,740,231 |
| Exchange | NASDAQ |
| Market Cap (intraday) | $3.07 M |
Corporate Structure
- Corporate Rebranding: Changed name from Carmell Corp to Longevity Health Holdings Inc on March 10, 2025.
- SEC Classification: Smaller reporting company and emerging growth company.
- Listing: Common stock (XAGE) and redeemable warrants (XAGEW) as of March 10, 2025.
- Executive Leadership:
- Rajiv Shukla, Chairman & CEO
- Patrick Sturgeon, Vice Chairman (founding team member, former CFO 2021–2023, Board Director since July 2023)
- Employee Count: Approximately 50–200 employees, supported by subsidiaries in bio-aesthetics, diagnostics, and analytics.
Recent Developments and News
- January 2025
- Acquisition of Elevai Skincare, Inc., adding a stem cell exosome-based product pipeline.
- March 10, 2025
- Stock symbols switched to XAGE (common) and XAGEW (warrants).
- Launch of new corporate logo; product branding remained unchanged.
- Appointment of Patrick Sturgeon as Vice Chairman.
- First Two Months of 2025
- Combined sales (Carmell + Elevai) up 34% compared to January and February 2024.
- Elevai’s burn rate reduced by over 50% through overhead savings.
- May 20, 2025
- Filed a prospectus supplement (Rule 424(b)(3)) to issue 1,331,452 shares of common stock at $3.81 per share.
- May 21, 2025
- Current Report on Form 8-K (Items 8.01 & 9.01) detailing material updates including financial statements and exhibits.
Financial and Strategic Analysis
Key Financial Metrics (TTM as of May 2025)
| Metric | Value |
|---|---|
| Revenue | $560.7 k |
| Net Income (Loss) | –$8.6 M |
| Diluted EPS | –11.87 |
| Price/Sales | 4.20 |
| Enterprise Value/Revenue | 5.04 |
| Total Cash (mrq) | $770.1 k |
| Levered Free Cash Flow | $437.6 k |
Guidance and Capital Raising
- FY2025 Revenue: $3 M to $4 M expected from existing product lines, excluding the potential impact of future partnerships and product launches.
- Q2 2025 Product Launches:
- Hair Growth Serum
- Soapless Facial Cleanser
- Undereye Crème
- VSA Toning Moisturizer
Strategic Positioning
- Business Focus: Core offerings in bio-aesthetics (including allogeneic PRP Secretome) with planned expansion into diagnostics and nutrition.
- Growth Strategy: Combination of organic product development, strategic partnerships, and acquisitions.
- Balance Sheet: Modest cash reserves counterbalanced by net losses; focus on fiscal discipline as an emerging growth company.
Market Position and Industry Context
- Sector: Regenerative bio-aesthetics and healthy aging, with implications for diagnostics and consumer wellness.
- Competitive Landscape: Small-cap peers on NASDAQ; currently profitability is limited, but the company is positioned for growth through acquisitions and new product introductions.
- Regulatory and Operational Risks: Subject to healthcare regulations, reimbursement changes, and integration challenges from acquisitions.
tl;dr
– Rebranded from Carmell Corporation to Longevity Health Holdings Inc on March 10, 2025; ticker changed to XAGE.
– January 2025 acquisition of Elevai Skincare contributed to a 34% increase in sales in January and February 2025 and halved its burn rate.
– Filed to issue 1.33 M shares at $3.81 on May 20, 2025, to support growth initiatives.
– FY2025 revenue guidance of $3–4 M; four new skincare and serum products scheduled for launch in Q2 2025.